BioCentury
ARTICLE | Clinical News

Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

April 4, 2019 10:34 PM UTC

Kolon TissueGene suspended enrollment in a U.S. Phase III trial of Invossa after finding that the osteoarthritis therapy's TGFB1-expressing component is derived from kidney cells rather than cartilage cells as it previously thought.

Kolon TissueGene Inc. (KOSDAQ:950160) was off KrW700 to KrW19,850 on Thursday, and is down 42% since it announced the news in a regulatory filing Monday...